Cardio Diagnostics Partners with 15 Providers to Enhance Heart Health

Cardio Diagnostics Holdings, Inc. has announced a significant expansion of its provider network by partnering with 15 new healthcare organizations across the United States as of October 21, 2025. This strategic move aims to enhance the accessibility of its innovative blood tests, Epi+Gen CHDTM and PrecisionCHDTM, which are designed to transform the prevention, detection, and management of coronary heart disease.

The new partnerships span various medical specialties and care models, covering four primary regions: Northeast, South, Midwest, and West. By integrating these advanced tests into their practices, healthcare providers will utilize Cardio Diagnostics’ cutting-edge epigenetic-genetic testing technology. This integration allows for actionable insights into coronary heart disease and heart attack risk, thereby facilitating personalized treatment plans for patients.

As cardiovascular disease increasingly impacts diverse patient demographics, the introduction of these tests is a critical response to the growing need for effective heart health management. The addition of 15 new provider partners marks a pivotal milestone in Cardio Diagnostics’ mission to broaden the reach of Precision Cardiovascular Medicine.

Strengthening Patient Care Across the Nation

“This expansion reflects the strong momentum we’re building in the provider community,” stated Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. She emphasized that the partnerships encompass a wide range of care models, such as concierge and functional medicine, as well as direct primary care. This diverse approach highlights the increasing recognition among healthcare providers of the value that precision medicine brings to patient care.

By equipping these practices with Epi+Gen CHDTM and PrecisionCHDTM, Cardio Diagnostics is not only enhancing patient care but also fostering improved health outcomes. The company aims to make its innovative cardiovascular solutions more accessible to patients throughout the country, especially as healthcare providers adopt evidence-based strategies to support cardiovascular health.

The tests offered by Cardio Diagnostics uniquely combine epigenetics, genetics, and artificial intelligence (AI) to deliver comprehensive insights into heart attack risk and the presence of coronary heart disease. These tools are crucial for early detection and ongoing management, particularly as coronary heart disease remains the leading cause of death globally.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. is an AI-powered precision cardiovascular medicine company dedicated to making cardiovascular disease prevention, detection, and management more accessible and personalized. Established to advance clinical tests, the company leverages its proprietary AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, positioning itself as a leader in medical technology for cardiovascular health.

For more information about Cardio Diagnostics and its innovative solutions, visit their website at https://cdio.ai/.

The company also issued a cautionary note regarding forward-looking statements, acknowledging the inherent risks and uncertainties involved in business operations, including economic conditions and regulatory changes. These factors could significantly affect the company’s financial performance and future results, as detailed in its Annual Report on Form 10-K for the period ended December 31, 2024.

This latest expansion underlines Cardio Diagnostics’ commitment to enhancing cardiovascular health through innovative technologies and partnerships that prioritize patient care and outcomes.